# **Special Issue**

## **Human Norovirus**

## Message from the Guest Editors

Dear Colleague, Human norovirus (HuNoV) causes approximately 18% of all gastroenteritis cases in all ages and is recognized as the leading cause of gastroenteritis outbreaks around the world. While the prevalence of HuNoV disease seems to be similar across the continents, an overwhelming majority of HuNoV-associated deaths occur in WHO-defined developing countries. HuNoV disease also has a significant economic impact, with an estimated global economic burden of USD 60.3 billion dollars per year, including health care costs and productivity loses. Concerted efforts to control HuNoV disease face major challenges, including: the genetic diversity of virus and ongoing evolution, strain-restrictive culture systems with low efficiency, and the limited knowledge of host factors that play a role in HuNoV infection, and protective immunity against HuNoV. The periodical emergence of novel HuNoV strains leading to global pandemics is also a major concern. The vast genetic diversity of HuNoV imposes a hurdle for the development of a vaccine that can provide broad coverage across all strains.

### **Guest Editors**

Dr. Xiaoli Pang

- 1. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada
- 2. Public Health Laboratories (ProvLab), Alberta Precision Laboratories (APL), Edmonton, AB, Canada

Dr. Bonita Lee

Department of Pediatrics, University of Alberta, Edmonton, AB, Canada

### Deadline for manuscript submissions

closed (15 December 2022)



## **Viruses**

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/113509

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





# Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

### **Editor-in-Chief**

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

### **Journal Rank:**

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

